These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31396953)

  • 1. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.
    Galaine J; Turco C; Vauchy C; Royer B; Mercier-Letondal P; Queiroz L; Loyon R; Mouget V; Boidot R; Laheurte C; Lakkis Z; Jary M; Adotévi O; Borg C; Godet Y
    Int J Cancer; 2019 Dec; 145(11):3112-3125. PubMed ID: 31396953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
    Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
    Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
    Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
    Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
    Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.
    Loyon R; Jary M; Salomé B; Gomez-Cadena A; Galaine J; Kroemer M; Romero P; Trabanelli S; Adotévi O; Borg C; Jandus C
    Front Immunol; 2019; 10():2121. PubMed ID: 31555301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
    Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
    J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
    Wang H; Li H; Zhang L; Yang D
    Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.
    Ghanbarian M; Afgar A; Yadegarazari R; Najafi R; Teimoori-Toolabi L
    Biomed Pharmacother; 2018 Dec; 108():1070-1080. PubMed ID: 30372807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thioredoxin domain-containing protein 9 (TXNDC9) contributes to oxaliplatin resistance through regulation of autophagy-apoptosis in colorectal adenocarcinoma.
    Zhou W; Fang C; Zhang L; Wang Q; Li D; Zhu D
    Biochem Biophys Res Commun; 2020 Apr; 524(3):582-588. PubMed ID: 32029274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model.
    Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q
    Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
    Maccalli C; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    Cancer Res; 2003 Oct; 63(20):6735-43. PubMed ID: 14583468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
    Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
    Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Hu J; Cai G; Xu Y; Cai S
    Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
    Tarpgaard LS; Qvortrup C; Nygård SB; Nielsen SL; Andersen DR; Jensen NF; Stenvang J; Detlefsen S; Brünner N; Pfeiffer P
    BMC Cancer; 2016 Feb; 16():91. PubMed ID: 26867764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
    Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
    Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
    Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.